The latest update is out from Shanghai Fosun Pharmaceutical (Group) Co ( (HK:2196) ).
Shanghai Fosun Pharmaceutical (Group) Co., Ltd. has announced a board meeting scheduled for March 25, 2025, to consider and approve the company’s final results for the year ending December 31, 2024. The meeting will also discuss the recommendation of a final dividend and other business matters, indicating a focus on financial performance and shareholder returns.
More about Shanghai Fosun Pharmaceutical (Group) Co
Shanghai Fosun Pharmaceutical (Group) Co., Ltd. is a joint stock company incorporated in China, operating in the pharmaceutical industry. The company focuses on the development, manufacturing, and sale of pharmaceutical products and medical devices, with a market presence in both domestic and international sectors.
YTD Price Performance: 7.95%
Average Trading Volume: 5,322
Technical Sentiment Consensus Rating: Hold
Current Market Cap: $8.38B
For an in-depth examination of 2196 stock, go to TipRanks’ Stock Analysis page.
Trending Articles:
Questions or Comments about the article? Write to editor@tipranks.com